1990-2019年中国乙型肝炎肝病死亡率趋势：全球疾病负担研究

StephenW

1990-2019年中国乙型肝炎肝病死亡率趋势：全球疾病负担研究结果
曹桂英 1、刘珏、刘敏
隶属关系
联系

    1
    北京大学公共卫生学院流行病学与生物统计学系, 北京 100191

    PMID: 36228164 DOI: 10.1097/CM9.0000000000002331

抽象的

背景：乙型肝炎是一种攻击肝脏的病毒感染，可导致潜在的危及生命的急性和慢性肝病。中国是世界上乙型肝炎负担最重的国家，被认为是实现世界卫生组织 (WHO) 到 2030 年消除作为全球健康威胁的乙型肝炎病毒 (HBV) 目标的主要贡献者。本研究旨在分析来自全球疾病负担、伤害和危险因素研究 (GBD) 旨在确定 1990 年至 2019 年中国乙型肝炎导致的肝病死亡率趋势以及与世界卫生组织目标的差距。

方法：从 GBD 2019 中收集 1990 年至 2019 年中国乙型肝炎肝病的年死亡人数和年龄标准化死亡率（ASMRs）。乙型肝炎引起的肝病。

结果：在中国，乙型肝炎导致的肝病总死亡人数从2016年的22.9万人下降29.13%至2019年的16.2万人，ASMR平均下降4.92%（95%置信区间[CI]：4.45-5.39 %) 在此期间每年。乙肝肝病谱中，1990-2019年急性肝炎、肝硬化等慢性肝病、肝癌死亡人数分别下降74.83%、34.71%和23.34%，急性肝炎的ASMRs。 EAPC = -7.63；95% CI：-8.25，-7.00），肝硬化和其他慢性肝病（EAPC = -4.15；95% CI：-4.66，-3.65）和肝癌（EAPC = -5.17；95% CI: -6.00, -4.33) 在 1990 年至 2019 年期间下降。1990 年至 2019 年，在所有因乙型肝炎导致的肝病死亡中，年龄≥70 岁的老年人比例有所增加。因乙型肝炎导致的肝癌死亡从 2015 年到 2019 年增长了 7.05%。

结乙肝引起的肝病，特别是乙肝引起的肝癌的诊治在中国是必要的。

版权所有 © 2022 中华医学会，由 Wolters Kluwer, Inc. 在 CC-BY-NC-ND 许可下制作。

StephenW

Trends in mortality of liver disease due to hepatitis B in China from 1990 to 2019: findings from the Global Burden of Disease Study
Guiying Cao  1 , Jue Liu, Min Liu
Affiliations
Affiliation

    1
    Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China.

    PMID: 36228164 DOI: 10.1097/CM9.0000000000002331

Abstract

Background: Hepatitis B is a viral infection that attacks the liver and can cause both potentially life-threatening acute and chronic liver disease. China has the world's largest burden of hepatitis B and is considered to be a major contributor toward the goal of World Health Organization (WHO) of eliminating hepatitis B virus (HBV) as a global health threat by 2030. This study aimed to analyze data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) to determine the trends in mortality of liver disease due to hepatitis B in China between 1990 and 2019 and the gap with the WHO's goal.

Methods: Annual deaths and age-standardized mortality rates (ASMRs) of liver disease due to hepatitis B in China between 1990 and 2019 were collected from GBD 2019. We calculated the percentage changes in deaths and estimated annual percentage changes (EAPCs) of ASMRs of liver disease due to hepatitis B.

Results: In China, deaths of total liver disease due to hepatitis B decreased by 29.13% from 229 thousand in 2016 to 162 thousand in 2019, and ASMR decreased by an average of 4.92% (95% confidence interval [CI]: 4.45-5.39%) per year in this period. For the spectrum of liver disease due to hepatitis B, deaths decreased by 74.83%, 34.71%, and 23.34% for acute hepatitis, cirrhosis and other chronic liver diseases, and liver cancer from 1990 to 2019, respectively, and ASMRs of acute hepatitis (EAPC = -7.63; 95% CI: -8.25, -7.00), cirrhosis and other chronic liver diseases (EAPC = -4.15; 95% CI: -4.66, -3.65), and liver cancer (EAPC = -5.17; 95% CI: -6.00, -4.33) decreased between 1990 and 2019. The proportions of older adults aged ≥70 years among all deaths of the spectrum of liver disease due to hepatitis B increased from 1990 to 2019. Deaths of liver cancer due to hepatitis B increased by 7.05% from 2015 to 2019.

Conclusions: Although a favorable trend in the mortality of liver disease due to hepatitis B was observed between 1990 and 2019, China still faces challenges in achieving the WHO's goal of eliminating HBV as a public threat by 2030. Therefore, efforts to increase the coverage of diagnosis and treatment of liver disease due to hepatitis B, especially of liver cancer due to hepatitis B, are warranted in China.

Copyright © 2022 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.

StephenW

https://doi.org/10.1097/cm9.0000000000002331